Marketing licence issued
Athens/Nikosia - Drug developer Samaritan Europe has entered into an exclusive distribution agreement with Three Rivers Pharmaceuticals for the marketing and sales of Amphocil® (amphotericin B cholesteryl sulfate complex for injection) in Greece and Cyprus. Amphocil is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immuno-compromised patients.
„Three Rivers Pharmaceuticals is very pleased to be partnering with Samaritan Europe,“ stated Donald J. Kerrish, President and CEO of the British distributor. „This distribution agreement is a welcome addition to our existing partnerships in Europe, and it demonstrates Three Rivers commitment to grow globally.“
Dr. Greeson, CEO of Samaritan stated: „We are thrilled with the Three Rivers Pharmaceuticals agreement as it enables Samaritan Europe to swiftly implement our marketing and sales arm in Greece, Cyprus and other designated countries.“ Amphocil is a specialty niche product targeted for immuno-compromised patients; marketing to HIV physicians complements Samaritan's focused indications.